SPAC JATT II to Merge with Talawar Therapeutics, Creating New Biotech Public Company
JATT sits 17% above its 52-week low of $10 on light trading volume (0.1× avg).
Summary
JATT II Acquisition Corp. has entered into a definitive business combination agreement with Talawar Therapeutics, a private biotechnology company. This merger will take Talawar Therapeutics public, fulfilling the SPAC's primary objective. This follows JATT II's $60 million IPO earlier this year, marking a significant milestone in its lifecycle. The agreement provides Talawar with access to public market capital.
At the time of this announcement, JATT was trading at $11.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.5M. The 52-week trading range was $10.00 to $12.01. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.